2012 Fiscal Year Final Research Report
Development of new renal regenerative therapy using human Renal-iPScells regulated by NF-kappaB
| Project/Area Number |
22590878
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Kidney internal medicine
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
TAKASE Osamu 東京大学, 医学部附属病院, 特任助教 (60265684)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HISHIKAWA Keiichi 東京大学, 医学部附属病院, 特任准教授 (50255460)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
FUJITA Toshiro 東京大学, 先端科学技術研究センター, 教授 (10114125)
ABURATANI Hiroyuki 東京大学, 先端科学技術研究センター, 教授 (10202657)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Keywords | 腎臓由来iPS細胞 / NF-kappaB / siRNA Knockdown / HDAC阻害剤 / エピジェネティク・メモリー |
|---|
| Research Abstract |
We have investigated about the differentiation toward to kidney using human Renal-iPS (hR-iPS) cells regulated by NF-kB as compared with human Fibroblastic-iPS (hF-iPS) cells. Both iPS cells have shown the activity of NF-kB. As NF-kB activity was knockdown by NF-kB p65 siRNA, the expression of undifferentiated makers decreased, conversely the kidney-associated-differentiated makers increased, especially stronger in hR-iPS than hF-iPS cells. Thus we have suggested that the augmentation of NF-B signaling maintains the undifferentiated state of human iPS, and hR-iPS cells are easy of differentiation toward to kidney. We have reported a part of outcome at the annual meeting of the Japanese Society of Nephrology, Japanese Society of Regenerative Medicine, and to the Journal of ‘PLoS One’.
|
Research Products
(11 results)
-
[Journal Article] The role of NF-κB signaling in the maintenance of pluripotency of human induced pluripotent stem cells.2013
Author(s)
Takase O, Yoshikawa M, Idei M, Hirahashi J, Fujita T, Takato T, Isagawa T, Nagae G, Suemori H, Aburatani H, Hishikawa K.
-
Journal Title
PLoS One.
Volume: 8(2)
Pages: e56399
DOI
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
